WS #15033
Competition in the obesity drug market is heating up as Eli Lilly's new Foundayo formulation demonstrates superior weight loss compared to oral semaglutide, and Hengrui Pharma secures a $2.6 billion licensing deal with Novo Nordisk for a once-weekly oral GLP-1/GIP agonist. These developments validate the massive demand for oral obesity treatments but intensify the competitive landscape for Lilly and Novo. Investors should watch for margin pressure as pricing power becomes a key differentiator in this crowded space.
GLP-1 Market Competition
Competition in the obesity drug market is heating up as Eli Lilly's new Foundayo formulation demonstrates superior weight loss compared to oral semaglutide, and Hengrui Pharma secures a $2.6 billion licensing deal with Novo Nordisk for a once-weekly oral GLP-1/GIP agonist. These developments validate the massive demand for oral obesity treatments but intensify the competitive landscape for Lilly and Novo. Investors should watch for margin pressure as pricing power becomes a key differentiator in this crowded space.